Common colorectal cancer risk variants in SMAD7 are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: A population-based study of postmenopausal women

Genes Chromosomes and Cancer

Volumn 50, Issue 11, 2011, Pages 875-886

  Passarelli, Michael N ^a,b   Coghill, Anna E ^a,b   Hutter, Carolyn M ^a,b   Zheng, Yingye ^a,b   Makar, Karen W ^a,b   Potter, John D ^a,b   Newcomb, Polly A ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; SMAD7 PROTEIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

ADENOCARCINOMA; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PROSPECTIVE STUDIES; SMAD7 PROTEIN;

EID: 80052674274     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20913     Document Type: Article

References (50)

1. Akhurst RJ, Derynck R. 2001. TGF-beta signaling in cancer-A double-edged sword. Trends Cell Biol 11: S44-S51.
2. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. 2001. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59: 901-908.
3. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JR. 2007. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 99: 881-889.
4. Bellam N, Pasche B. 2010. Tgf-beta signaling alterations and colon cancer. Cancer Treat Res 155: 85-103.
5. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S, Sullivan K, Fielding S, Jaeger E, Vijayakrishnan J, Kemp Z, Gorman M, Chandler I, Papaemmanuil E, Penegar S, Wood W, Sellick G, Qureshi M, Teixeira A, Domingo E, Barclay E, Martin L, Sieber O, Kerr D, Gray R, Peto J, Cazier JB, Tomlinson I, Houlston RS. 2007. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 39: 1315-1317.
6. Calle EE, Terrell DD. 1993. Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants. Am J Epidemiol 137: 235-241.
7. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. 2005. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294: 914-923.
8. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, Potter JD, Ulrich CM. 2011a. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 60: 491-498.
9. Coghill AE, Newcomb PA, Chia VM, Zheng Y, Wernli KJ, Passarelli MN, Potter JD. 2011b. prediagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women. Br J Cancer 104: 763-768.
10. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. 2009. Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials. J Natl Cancer Inst 101: 256-266.
11. Curtin K, Lin WY, George R, Katory M, Shorto J, Cannon-Albright LA, Bishop DT, Cox A, Camp NJ. 2009. Meta association of colorectal cancer confirms risk alleles at 8q24 and 18q21. Cancer Epidemiol Biomarkers Prev 18: 616-621.
12. Elliott RL, Blobe GC. 2005. Role of transforming growth factor Beta in human cancer. J Clin Oncol 23: 2078-2093.
13. Enders GA. 2007. Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-beta. Br J Cancer 97: 1388-1392.
14. Flossmann E, Rothwell PM. 2007. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 369: 1603-1613.
15. Försti A, Li X, Wagner K, Tavelin B, Enquist K, Palmqvist R, Altieri A, Hallmans G, Hemminki K, Lenner P. 2010. Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression. Genes Chromosomes Cancer 49: 270-281.
16. Fritz AG. 2000. International Classification of Diseases for Oncology: ICD-O, 3rd ed. Geneva: World Health Organization.
17. Fukushima T, Mashiko M, Takita K, Otake T, Endo Y, Sekikawa K, Takenoshita S. 2003. Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6, and Smad7 genes in colorectal cancer. J Exp Clin Cancer Res 22: 315-320.
18. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. 1994. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241-246.
19. Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, Denobile J, Soballe P, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. 2006. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 15: 1382-1391.
20. Gupta RA, Dubois RN. 2001. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21.
21. Halder SK, Beauchamp RD, Datta PK. 2005. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res 307: 231-246.
22. Hong S. 2010. Connection between inflammation and carcinogenesis in gastrointestinal tract: Focus on TGF-β signaling. World J Gastroenterol 16: 2080-2093.
23. Hong S, Lee C, Kim SJ. 2007. Smad7 sensitizes tumor necrosis factor induced apoptosis through the inhibition of antiapoptotic gene expression by suppressing activation of the nuclear factor-kappaB pathway. Cancer Res 67: 9577-9583.
24. Iguchi G, Chrysovergis K, Lee SH, Baek SJ, Langenbach R, Eling TE. 2009. A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2. Cancer Lett 282: 152-158.
25. Levy L, Hill CS. 2006. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58.
26. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, Young JP, Barker MA, Jass JR, Hopper J, Gallinger S, Bapat B, Redston M, Thibodeau SN. 2002. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20: 1043-1048.
27. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. 2000. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311.
28. Monteleone G, Pallone F, MacDonald TT. 2004. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol 25: 513-517.
29. Monteleone G, Boirivant M, Pallone F, MacDonald TT. 2008. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol 1 (Suppl 1): S50-S53.
30. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P. 1997. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389: 631-635.
31. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, Hall D, Hopper JL, Jass J, Le Marchand L, Limburg P, Lindor N, Potter JD, Templeton AS, Thibodeau S, Seminara D. 2007a. Colon cancer family registry: An international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 16: 2331-2343.
32. Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, Thibodeau SN, Potter JD. 2007b. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res 67: 7534-7539.
33. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO. 2008. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 121: 3487-3495.
34. Pardali K, Moustakas A. 2007. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775: 21-62.
35. Pittman AM, Naranjo S, Webb E, Broderick P, Lips EH, van Wezel T, Morreau H, Sullivan K, Fielding S, Twiss P, Vijayakrishnan J, Casares F, Qureshi M, Gomez-Skarmeta JL, Houlston RS. 2009. The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. Genome Res 19: 987-993.
36. Roberts AB, Wakefield LM. 2003. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623.
37. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. 2003. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890.
38. Slattery ML, Herrick J, Curtin K, Samowitz W, Wolff RK, Caan BJ, Duggan D, Potter JD, Peters U. 2010. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res 70: 1479-1485.
39. Slattery ML, Herrick JS, Lundgreen A, Wolff RK. 2011. Genetic variation in the TGF-beta signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev 20: 57-69.
40. Slattery ML, Lundgreen A, Herrick JS, Wolff RK, Caan BJ. Genetic variation in the transforming growth factor-beta signaling pathway and survival after diagnosis with colon and rectal cancer. Cancer doi: 10.1002 [Epub ahead of print].
41. ten Dijke P, Hill CS. 2004. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29: 265-273.
42. Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, Barnetson RA, Theodoratou E, Cetnarskyj R, Cartwright N, Semple C, Clark AJ, Reid FJ, Smith LA, Kavoussanakis K, Koessler T, Pharoah PD, Buch S, Schafmayer C, Tepel J, Schreiber S, Volzke H, Schmidt CO, Hampe J, Chang-Claude J, Hoffmeister M, Brenner H, Wilkening S, Canzian F, Capella G, Moreno V, Deary IJ, Starr JM, Tomlinson IP, Kemp Z, Howarth K, Carvajal-Carmona L, Webb E, Broderick P, Vijayakrishnan J, Houlston RS, Rennert G, Ballinger D, Rozek L, Gruber SB, Matsuda K, Kidokoro T, Nakamura Y, Zanke BW, Greenwood CM, Rangrej J, Kustra R, Montpetit A, Hudson TJ, Gallinger S, Campbell H, Dunlop MG. 2008. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 40: 631-637.
43. Tenesa A, Theodoratou E, Din FV, Farrington SM, Cetnarskyj R, Barnetson RA, Porteous ME, Campbell H, Dunlop MG. 2010. Ten common genetic variants associated with colorectal cancer risk are not associated with survival after diagnosis. Clin Cancer Res 16: 3754-3759.
44. Thompson CL, Plummer SJ, Acheson LS, Tucker TC, Casey G, Li L. 2009. Association of common genetic variants in SMAD7 and risk of colon cancer. Carcinogenesis 30: 982-986.
45. Thun MJ, Namboodiri MM, Heath CWJr., 1991. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596.
46. Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, Spain S, Lubbe S, Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A, Vijayakrishnan J, Domingo E, Chandler I, Kemp Z, Qureshi M, Farrington SM, Tenesa A, Prendergast JG, Barnetson RA, Penegar S, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop DT, Gray R, Maher ER, Lucassen A, Kerr D, Evans DG, Schafmayer C, Buch S, Volzke H, Hampe J, Schreiber S, John U, Koessler T, Pharoah P, van Wezel T, Morreau H, Wijnen JT, Hopper JL, Southey MC, Giles GG, Severi G, Castellvi-Bel S, Ruiz-Ponte C, Carracedo A, Castells A, Forsti A, Hemminki K, Vodicka P, Naccarati A, Lipton L, Ho JW, Cheng KK, Sham PC, Luk J, Agundez JA, Ladero JM, de la Hoya M, Caldes T, Niittymaki I, Tuupanen S, Karhu A, Aaltonen L, Cazier JB, Campbell H, Dunlop MG, Houlston RS. 2008. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 40: 623-630.
47. Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M. 2003. Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J 9: 302-312.
48. Xu Y, Pasche B. 2007. TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet 16: R14-R20.
49. Young JL, Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. 2001. SEER Summary Staging Manual 2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute, NIH Pub. No. 01-4969.
50. Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, Neuhausen SL, Stram DO, Ursin G, Anton-Culver H. 2009. Nonsteroidal anti-inflammatory drugs: Effects on mortality after colorectal cancer diagnosis. Cancer 115: 5662-5671.